Senya secured a £680,000 non-dilutive grant from the highly competitive Innovate UK Investor Partnerships scheme for our preclinical work in nephrology and oncology. This is…
Read More
April 2023 Senya has signed a Memorandum of Understanding with the Netherlands Cancer Institute in collaborating for Phase I/II trial in cancer using STX-002, Senya’s…
Senya Therapeutics is launched with a primary focus on developing STX-002, its lead compound, for chronic kidney disease and immuno-therapy resistant tumours.
